In a recent post on the IVI-sponsored Health Affairs featured blog series, Claire Laporte explains why the patent process dispute between biosimilar and branded drug manufacturers is headed all the way to the Supreme Court and why the outcome could influence intellectual property laws and protections for trade secrets.
Read the full article here.
About the Health Affairs/IVI Featured Blog Series: Drugs and Medical Innovation — In partnership with Health Affairs, IVI is proud to sponsor the “Drugs and Medical Innovation” blog series. On an ongoing basis, articles in this series will explore topics such as value-based reimbursement, drug policy and pricing, balancing short-term access against long-term rates of innovation, and other relevant issues. Our goal is to create an open forum for sharing ideas and debating issues in these areas, extending the discussion to a broader audience.
